155 related articles for article (PubMed ID: 25586740)
21. Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway.
Tang XL; Yan L; Zhu L; Jiao DM; Chen J; Chen QY
J Pharmacol Sci; 2017 Sep; 135(1):1-7. PubMed ID: 28939129
[TBL] [Abstract][Full Text] [Related]
22. Stephania Tetrandra and Ginseng-Containing Chinese Herbal Formulation NSENL Reverses Cisplatin Resistance in Lung Cancer Xenografts.
Jin L; Xu M; Luo XH; Zhu XF
Am J Chin Med; 2017; 45(2):385-401. PubMed ID: 28231742
[TBL] [Abstract][Full Text] [Related]
23. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
24. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-448 targets SATB1 to reverse the cisplatin resistance in lung cancer via mediating Wnt/β-catenin signalling pathway.
Ning MY; Cheng ZL; Zhao J
J Biochem; 2020 Jul; 168(1):41-51. PubMed ID: 32525527
[TBL] [Abstract][Full Text] [Related]
26. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation.
Fang Z; Chen W; Yuan Z; Liu X; Jiang H
Biomed Pharmacother; 2018 May; 101():536-542. PubMed ID: 29505924
[TBL] [Abstract][Full Text] [Related]
27. Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin.
Hu W; Jin P; Liu W
Cell Physiol Biochem; 2016; 38(3):1199-208. PubMed ID: 26982182
[TBL] [Abstract][Full Text] [Related]
28. CircAKT3 inhibits glycolysis balance in lung cancer cells by regulating miR-516b-5p/STAT3 to inhibit cisplatin sensitivity.
Xu Y; Jiang T; Wu C; Zhang Y
Biotechnol Lett; 2020 Jul; 42(7):1123-1135. PubMed ID: 32170433
[TBL] [Abstract][Full Text] [Related]
29. Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway.
Danni X; Jiangzheng Z; Huamao S; Yinglian P; Changcheng Y; Yanda L
Bioengineered; 2021 Dec; 12(1):7335-7347. PubMed ID: 34612768
[TBL] [Abstract][Full Text] [Related]
30. Cryptotanshinone Reverses Cisplatin Resistance of Human Lung Carcinoma A549 Cells through Down-Regulating Nrf2 Pathway.
Xia C; Bai X; Hou X; Gou X; Wang Y; Zeng H; Huang M; Jin J
Cell Physiol Biochem; 2015; 37(2):816-24. PubMed ID: 26356271
[TBL] [Abstract][Full Text] [Related]
31. [Effect of XPA expression on the chemotherapy sensitivity of A549/DDP cells].
Zhang Q; Wu JX; Wei YP; Hao JQ; Huang SY; Dong L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1182-4. PubMed ID: 23127410
[TBL] [Abstract][Full Text] [Related]
32. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
[TBL] [Abstract][Full Text] [Related]
33. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
34. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.
Tao L; Huang G; Wang R; Pan Y; He Z; Chu X; Song H; Chen L
Sci Rep; 2016 Dec; 6():38408. PubMed ID: 27922075
[TBL] [Abstract][Full Text] [Related]
35. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer.
Zhang W; Wan M; Ma L; Liu X; He J
Cell Biol Int; 2013 Jan; 37(1):47-53. PubMed ID: 23319321
[TBL] [Abstract][Full Text] [Related]
37. EGCG inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells.
Liu LC; Tsao TC; Hsu SR; Wang HC; Tsai TC; Kao JY; Way TD
J Agric Food Chem; 2012 Oct; 60(39):9863-73. PubMed ID: 22957988
[TBL] [Abstract][Full Text] [Related]
38. [Effect of silencing Bmi-1 expression in reversing cisplatin resistance in lung cancer cells and its mechanism].
Mao N; He G; Rao J; Lv L
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jun; 34(7):1000-4. PubMed ID: 25057072
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
40. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway.
Zhang J; Zhang T; Ti X; Shi J; Wu C; Ren X; Yin H
Biochem Biophys Res Commun; 2010 Aug; 399(1):1-6. PubMed ID: 20627087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
